An Oral GLP-1 Just Hit 89% A1c Target

A new phase 2b trial of Eli Lilly’s investigational oral GLP-1 elecoglipron showed that up to 89.6% of participants with Type 2 diabetes reached an A1c of 7% or lower, compared with just 24.9% on placebo —
and up to 72.3% achieved at least 5% weight loss versus 20.2% on placebo. The results, presented this week at the American Diabetes Association’s 2026 Scientific Sessions, are the latest in a wave of oral GLP-1 data
reshaping the Type 2 treatment landscape, as detailed in the ADA 2026 coverage and the Eli Lilly press
release. For the 38 million Americans living with Type 2 diabetes, this is being framed as the moment a pill finally delivers injectable-level results. It is — for managing the disease. It is not, and cannot be, a reversal.

What Just Happened

The elecoglipron phase 2b results, presented at ADA 2026, showed strong glycemic and weight-loss efficacy for the once-daily oral GLP-1 in adults with Type 2 diabetes, as detailed in the Eli Lilly press release.

The headline numbers from the ADA 2026 Scientific Sessions coverage and the Lilly press release:

  • Trial design: Phase 2b, randomized, double-blind, placebo-controlled trial of elecoglipron in adults with Type 2 diabetes, with a 26-week primary endpoint, per the Lilly press release.
  • A1c target attainment: Up to 89.6% of participants on elecoglipron reached an A1c of 7% or lower, compared with 24.9% on placebo.
  • Weight loss: Up to 72.3% of participants on elecoglipron achieved at least 5% weight loss, versus 20.2% on placebo.
  • Mechanism: Elecoglipron is a once-daily oral small-molecule GLP-1 receptor agonist — no injections, no food or water restrictions, easier manufacturing than peptide GLP-1s, per the Lilly press release.
  • Safety profile: Adverse events were consistent with the GLP-1 class — predominantly GI (nausea, diarrhea, vomiting), generally mild to moderate, with low discontinuation rates.
  • The clinical interpretation: 89.6% A1c target attainment is one of the strongest single-agent results ever reported for an oral Type 2 diabetes therapy, per the Lilly press release.

The Question Nobody’s Asking

Here’s what every headline about the elecoglipron results is leaving out: even a 89% A1c target rate on a drug still manages diabetes. It does not reverse it.

Elecoglipron works by mimicking a single gut hormone — GLP-1 — that tells your pancreas to make more insulin, slows your stomach emptying, and quiets your hunger signals. You take it once a day. When you stop, the A1c climbs back. The weight comes back. The medication never addresses why your blood sugar was
dysregulated in the first place — it overrides the symptom while the underlying insulin resistance keeps running the show.

That’s not a flaw in elecoglipron. It’s an excellent result for a pill, and the 89% target-attainment rate is one of
the strongest single-agent data points in Type 2 diabetes in years. But “89% of patients hit A1c target on a drug” and “reversal of Type 2 diabetes” are two completely different games. A 7% A1c on medication is still a
diabetic A1c. A patient who hits 7% on elecoglipron is still diabetic. When they stop the pill, the disease comes back.

So the real question for the millions of Americans being told an oral GLP-1 will replace their injection isn’t
“which GLP-1 pill should I take?” It’s “why am I still diabetic in the first place, and what’s actually required
to reverse it?”

What Remission Actually Looks Like

At Diabetes Reversal Group, we measure reversal by a single, unblinking standard: A1c 6.4% or lower — off
every diabetes medication — sustained. Not “controlled.” Not “managed.”

Our patients hit remission in an average of 4.5 months. The mechanism isn’t a molecule. It’s a system: a patented nutrition protocol that reverses the underlying insulin resistance at the root.

The Bottom Line

An oral GLP-1 just hit 89% A1c target on a pill. It’s a real win for Type 2 management. A system that reverses
the disease is a different game entirely — one the pharmaceutical pipeline cannot build.

If you’re on metformin, a GLP-1, or insulin, and you’ve been told you’ll be on it for life, you owe it to yourself to
look at what’s actually possible. Watch our free webinar. No pitch. Just the science, the data, and how to know if you’re a candidate.

By: Dr. Jeffrey Hockings / Co-Founder/CEO / Diabetes Reversal Group / Kristine Burke, MD / Chief Medical
Officer / Diabetes Reversal Group. The only patented system in the world proven to reverse Type 2 diabetes.